KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Alnylam Pharmaceuticals (ALNY) Debt to Equity (2016 - 2025)

Historic Debt to Equity for Alnylam Pharmaceuticals (ALNY) over the last 8 years, with Q3 2025 value amounting to $0.52.

  • Alnylam Pharmaceuticals' Debt to Equity changed N/A to $0.52 in Q3 2025 from the same period last year, while for Sep 2025 it was $0.52, marking a year-over-year change of. This contributed to the annual value of $1.4 for FY2024, which is N/A changed from last year.
  • As of Q3 2025, Alnylam Pharmaceuticals' Debt to Equity stood at $0.52.
  • Alnylam Pharmaceuticals' Debt to Equity's 5-year high stood at $1.4 during Q4 2024, with a 5-year trough of $0.48 in Q2 2025.
  • Its 3-year average for Debt to Equity is $0.91, with a median of $1.02 in 2025.
  • Within the past 5 years, the most significant YoY rise in Alnylam Pharmaceuticals' Debt to Equity was 51032.2% (2021), while the steepest drop was 51032.2% (2021).
  • Over the past 3 years, Alnylam Pharmaceuticals' Debt to Equity (Quarter) stood at $1.15 in 2021, then increased by 21.71% to $1.4 in 2024, then crashed by 62.91% to $0.52 in 2025.
  • Its Debt to Equity was $0.52 in Q3 2025, compared to $0.48 in Q2 2025 and $1.02 in Q1 2025.